Broadcom named strategic vendor for Walmart virtualization solutions
Penumbra Inc ’s (NYSE:PEN) Chief Financial Officer, Maggie Yuen, recently sold 2,000 shares of the company’s common stock, totaling approximately $598,020. The shares were sold at a price of $299.01 each on May 2, 2025, near the company’s 52-week high of $310. With a market capitalization of $11.3 billion and revenue growth of ~13%, Penumbra maintains a "GREAT" financial health score according to InvestingPro analysis. Following this transaction, Yuen holds 13,957 shares directly.
Additionally, on May 6, Yuen exercised stock options to acquire 900 shares at a price of $158.30 per share, resulting in a total transaction value of $142,470. This exercise increased her direct ownership to 14,857 shares, with a portion of these shares subject to vesting.
The sales were conducted under Yuen’s Rule 10b5-1 trading plan, which allows company insiders to set up a predetermined plan to sell stocks. The company currently trades at a P/E ratio of 278, reflecting market expectations for future growth.
In other recent news, Penumbra has reported strong financial results for the first quarter of 2025, with earnings per share (EPS) of $0.83 and revenue reaching $324.1 million. This represents a year-over-year growth of 16.3% in revenue and a significant 102.8% increase in EPS, surpassing Wall Street estimates by 2.7% and 24.4%, respectively. The company’s U.S. Thrombectomy business was a key driver, generating $187.9 million in sales, marking a 25% increase. UBS, Stifel, and BTIG have all raised their price targets for Penumbra, reflecting confidence in the company’s growth trajectory. UBS set the target at $330, Stifel at $318, and BTIG at $320, with all firms maintaining a Buy rating. Penumbra’s management has reaffirmed its revenue guidance for the year, projecting a 12-14% increase. Additionally, the company has raised its U.S. Thrombectomy guidance to a growth range of 20-21% year-over-year. Penumbra’s strategic focus on the U.S. market and its innovative product launches, including the recent 510K submission for the THUNDERBOLT product, are contributing to its strong market position and positive outlook.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.